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We investigated structural brain differences between a group of early-mild PD patients at different phases of the disease and healthy
subjects using voxel-based morphometry (VBM). 20 mild PD patients compared to 15 healthy at baseline and after 2 years of
follow-up. VBM is a fully automated technique, which allows the identification of regional differences in the gray matter enabling
an objective analysis of the whole brain between groups of subjects. With respect to controls, PD patients exhibited decreased GM
volumes in right putamen and right parietal cortex. After 2 years of disease, the samepatients confirmedGM loss in the putamen and
parietal cortex; a significant difference was also observed in the area of pedunculopontine nucleus (PPN) and in the mesencephalic
locomotor region (MLR). PD is associated with brainmorphological changes in cortical and subcortical structures.The first regions
to be affected in PD seem to be the parietal cortex and the putamen. A third structure that undergoes atrophy is the part of the
inferior-posterior midbrain, attributable to the PPN and MLR. Our findings provide new insight into the brain involvement in PD
and could contribute to a better understanding of the sequence of events occurring in these patients.
1. Introduction
Neuropathological studies in Parkinson’s disease (PD) have
proposed a six-phase progression system, indicating a grow-
ing and predictable sequence of brain pathology related to
neurological deficits presented by patients at different stages
of the disease [1]. However this classification often does not
timely correlate with clinical severity or with onset of specific
aspects of the symptomatology, such as postural or cognitive
symptoms [2].
Only few studies investigated PD patients with short-
disease duration. These studies reported no changes [3], lat-
eral andmedial frontal atrophy [4, 5], hippocampal/amygdala
atrophy [4, 6, 7], and left cerebellum atrophy [8]. The
purpose of this study was to identify cortical and subcortical
structural changes at an early stage of PD and to evaluate their
progression over 2 years.
The longitudinal evaluation of brain atrophy in patients
with PD has been studied only in few studies with contra-
dictory results. In fact, while Ramı́rez-Ruiz and collaborators
showed the presence of a reduction of gray matter in several
cortical areas [9], Brenneis and collaborators comparing a
group of patients suffering from PD and a group of patients
with multisystem atrophy (MSA-P) found a progression of
the atrophy only in the group of patients withMSA-P, but not
in patients with PD [10].
This lack of consistency is due to several factors in
between-group design (e.g., number of samples, duration of
the disease, variability in symptom characteristics, severity of
illness, etc.). In light of this limitation, we opted for a within-
group design to explore the effect of progression of the disease
on brain atrophy in a group of PD patients.
2. Methods
2.1. Subjects. A group of 25 patients with PD were recruited
at the Ambulatory of Movement Disorders at the Nuovo
Ospedale Sant’Agostino-Estense (Modena). Fifteen healthy
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Table 1: Sociodemographic and clinical characteristics of the
two study groups. Values denote mean (± standard deviation) or
numbers of subjects.
PD patients𝑁 = 20 Controls𝑁 = 15
Sociodemographics
Age (years) 60.5 (±7.7) 64.6 (±4.8)
Sex (male/female) 12/8 8/7
Education (years) 9.75 (±3.76) 11.3 (±3.19)
Clinical characteristics
Duration of illness (years) 5.17 (±4.14)
Age at diagnosis (years) 55.20 (±8.44)
Baseline (test) OFF-drug
UPDRS I 2.50 (±1.84)
UPDRS II 8.55 (±3.88)
UPDRS III 26.6 (±7.12)
H&Y scale 2.42 (±0.25)
Retest OFF-drug
UPDRS I 2.61 (±1.50)
UPDRS II 9.76 (±5.21)
UPDRS III 22.46 (±6.02)
H&Y scale 2.71 (±0.26)
Equivalent dose of
dopaminergic drug
Test (mg) 473.5 (±238.0)
Retest (mg) 650.3 (±272.9)
At baseline, all subjects underwent magnetic resonance
imaging (MRI) scan, physical examination, and neuropsy-
chological assessment. Those with a poor quality MRI scan
or evidence of previous stroke were not included.
In summary, 20 PD patients (mean age = 63 yrs; 12 males
and 8 females) and 15 age, gender, and educationmatchedHV
(mean age = 65 yrs; 8 males and 7 females) were included in
the imaging analyses (Table 1).
Patients were diagnosed according to the UK Brain Bank
criteria [11]. All patients used dopaminergic medication (lev-
odopa or dopamine agonists). Disease severity was assessed
using the Hoehn and Yahr stages and Unified Parkinson’s
Disease Rating Scale (UPDRS) in OFF-drug condition (at
least 18 h following intake of the last dose of levodopa and
36 h after other antiparkinsonismmedications). Patients were
reassessed clinically andMRI after 2 years (mean = 25.5 ± 4.9
months).
The study was approved by the local ethics committee
andwritten informed consentwas obtained fromparticipants
prior to the experiment according to the Declaration of
Helsinki.
2.2.MRIAcquisition. Scanningwas performed at theDepart-
ment of Neuroscience-Baggiovara, Hospital of Modena Uni-
versity. Three-dimensional (3D) T1-weighted MRI images
were acquired using a 3 Tesla Philips Intera MRI scanner. A
SPGR pulse sequence (echo time (TE) = 4.6, repetition time
(TR) = 9.9ms) was used. One hundred seventy contiguous
sagittal slices were acquired (voxel size = 1 × 1 × 1mm) and
field of viewwas 240mmwith amatrix size of 256× 256× 170.
A T2-weighted axial scan and a coronal fluid attenuated
inversion recovery (FLAIR) scan were also acquired to have
a better definition of possible vascular damage.
2.3. Voxel-Based Morphometry (VBM) Analyses. The opti-
mized VBM protocol was implemented within Matlab 7.1
(Mathworks, Natick, Mass.) through Statistical Parametric
Mapping 8 (SPM8Wellcome Trust Centre for Neuroimaging,
London UK).
2.3.1. Preprocessing. Preprocessingwas performedusingVBM8
(http://dbm.neuro.uni-jena.de/vbm/). This is an improved
version of the standard SPM-VBM procedure described in
detail elsewhere [12] and already used in previous studies
[12, 13]. In brief, VBM8 comprised several processes: nor-
malization, segmentation, modulation, and smoothing. The
normalization step put the individual images in a common
space: images were spatially normalized to a widely used T1-
weighted MRI template in stereotaxic space, the Montreal
Neurological Institute/International Consortium for Brain
Mapping (MNI/ICBM) 152 standard. In this step, voxel size
was resampled to 1.5 × 1.5 × 1.5mm. Then images were
segmented in GM, white matter (WM), and cerebrospinal
fluid (CSF) volumes. Volumes were then modulated with
Jacobian determinants. Modulation involves scaling by the
amount of contraction, so that the total amount of GM in the
modulated GM volumes remains the same, as it would be in
the original images. Finally, segments were smoothed using a
12 × 12 × 12 kernel.
2.3.2. Whole Brain Analysis. Total GM volumes of normal-
ized-modulated images were compared between PD-baseline
versus healthy subjects and PD-follow-up versus healthy
subjects using a two-sample 𝑡-test. Since we had to com-
pare the same group (patients at baseline and follow-up;
dependent samples) with controls (independent samples), a
single ANOVA could not be performed so we decided to
evaluate the difference with separate 𝑡-test for independent
samples. For the 𝑡-test the statistical threshold was set at
𝑃 ≤ 0.001 uncorrected for multiple comparison. The
extended threshold was differently set at baseline and follow-
up analysis according to SPM approach. For the small volume
correction (SVC) the threshold was set at 𝑃 < 0.05 with
familywise error (FWE) correction [13].
In the 𝑡-test we used age and TIV (total intracranial
volume) as covariates of no interest. In addition, separate cor-
relation analyses were run on the PD data using the following
clinical scores: Hoehn and Yahr stages UPDRS scores and
disease duration and therapy (levodopa equivalent dose).
The coordinates of significant voxels were converted from
MNI space [14] to Talairach and Tournoux coordinates [15]
using aMatlab function developed byM.Brett (mni2tal http://
imaging.mrc-cbu.cam.ac.uk/imaging/MniTalairach). Subcor-
tical anatomical regions were identified using the stereotactic
atlas of Schaltenbrand-Wahren [16] second edition and the
Nieuwenhuys-Voogd-Van Huijzen atlas [17].
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Table 2: Grey matter reduction in PD patients with respect to controls at baseline (test).
Cluster 𝑘 Voxel 𝑍 Level 𝑃 MNI coord. 𝑥, 𝑦, 𝑧 (mm)
R, parietal lobe (BA 40) 257 3.37 <0.001 48, −72, 45
R, angular gyrus (BA 39); R, precuneus (BA 31)
R, inferior parietal lobule (BA 7) 39, −65, 32
R, putamen∗ 57 3.77 <0.05 26, −3, 9
𝑃 < 0.001 uncorrected for multiple comparisons (voxel level 𝑘 > 241 voxels).
∗Correction svc 𝑃 = 0.05 (FWE).















Figure 1: Surface rendering (a) and sagittal sections (b) showing the grey matter reduction in PD patients with respect to controls at
baseline (test). Numbers below each sagittal slice represent the 𝑥 coordinate in MNI space. Clusters are superimposed on the MNI template
implemented in SPM8 (𝑃 = 0.001 uncorrected; 𝑘 > 241 voxels).
3. Results
3.1. Baseline. We first tested the GM differences between PD
patients andHV at baseline.The PD group showed decreased
GM volume distributed in the right hemisphere, especially
in the precuneus and in the parietal lobe (BA 39, BA 40,
and BA 7; Table 2 and Figure 1). Additional GM loss was also
identified in right putamen. At a less conservative threshold a
symmetrical cluster has been observed also in the left parietal
lobe.
No significant correlation with clinical parameters was
found.
No significant increased GM volume in PD patients
relative to controls was found.
3.2. Follow-Up Study. The comparison between PD patient
after two years of follow-up and HV revealed that the PD
group showed the same regions of GM loss found at baseline,
but wider, involving the right parietal lobe (BA 39, BA 40, BA
7, and BA 31) and the right putamen (Table 3 and Figure 2).
As observed before, a symmetrical not significant decrease of
the gray matter was found in the left parietal lobe. Moreover,
an additional GM loss cluster was found in the midbrain, in a
region identified as themesencephalic locomotor region (MLR,
Figure 2). A similar cluster could be detected at baseline at
a less conservative threshold. No significant correlation with
UPDRS motor score (considered as a whole, and for specific
postural control and path items) was found (UPDRS item
29 = 1.0 ± 0.8 at follow-up; UPDRS item 30 score of 0.9 ± 0.3
at baseline and 1.0 ± 0.4 at follow-up).
4. Discussion
We investigated structural brain differences between groups
of healthy subjects and patients with PDusingVBM.We eval-
uated patients at baseline and after two years of disease pro-
gression in OFF condition, after a pharmacological washout.
The VBM analysis at baseline showed areas of GM loss in the
right hemisphere, in particular in the putamen and parietal
lobe. These regional atrophies were enlarged after two years
of follow-up, where a new cluster in midbrain was also noted.
4.1. Putamen. Structural and functional alterations of the
putamen have been widely documented in literature, using
different methods. Péran et al. have shown the presence of
alterations in the mean diffusivity in the striatum and in
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Table 3: Grey matter reduction in PD patients with respect to controls at retest.
Cluster 𝑘 Voxel 𝑍 Level 𝑃 MNI coord. 𝑥, 𝑦, 𝑧 (mm)
R, parietal lobe (BA 40) 449 3.56 <0.001 48, −72, 46
R, angular gyrus (BA 39); R, precuneus (BA 31)
R, inferior parietal lobule (BA 7)
R, superior occipital gyrus (BA 19) 3.34 <0.001 39, −69, 31
R, putamen∗ 25 3.47 <0.05 24, −3, 10
Midbrain∗ 176 3.53 <0.05 2, −27, −17
𝑃 < 0.001 uncorrected for multiple comparisons (voxel level 𝑘 > 241 voxels).
∗Correction SVC 𝑃 = 0.05 (FWE).












Figure 2: Surface rendering (a) and sagittal sections (b) showing the grey matter reduction in PD patients with respect to controls at retest.
Numbers below each sagittal slice represent the 𝑥 coordinate in MNI space. Clusters are superimposed on the MNI template implemented in
SPM8 (𝑃 = 0.001 uncorrected; 𝑘 > 223 voxels).
particular in the right putamen [18] in a group of thirty
patients with PD. A dopamine binding transporter loss in
this region has been found and neuropathological studies
confirmed the presence of microscopic structural alterations
such as deposition of Lewy bodies and accumulation of neu-
rofibrillary in the same structures [19].Molecular studies have
recently confirmed the presence of a striatal progressive den-
ervation and atrophy caused by the decrease in dopaminergic
afferences due to neuronal loss in the substantia nigra [20].
The GM loss in the putamen in patients at mild to mod-
erate stages of the disease is expected because a significant
degeneration of dopaminergic nigrostriatal system precedes
the onset of motor symptoms of PD. The right localization
did not correlate with the onset side of symptoms nor with
the handedness. Although apparently conflicting with data,
PD symptoms seem to emerge more often on the dominant
hand-side [21]. On the contrary, atrophy does not necessarily
depend on nigrostriatal degeneration, which is usually more
severe contralaterally to the more affected side. Moreover,
it is known that the precentral motor cortex projects to the
putamen and to other structures of the basal ganglia of both
sides [22]. Therefore, this asymmetry may be related to the
complex bilateral connections in the motor system that does
not fulfill the side prevalence of clinical signs.
4.2. Parietal Cortex. The atrophy was found in the right
parietal regions, in particular in the precuneus (PC) and
in the angular gyrus (AG). This GM loss was wider in the
follow-up analysis, in agreementwith the disease progression.
Several studies have shown the presence of atrophy in these
parietal areas in PD patients [23, 24], without consistent
differences between the two hemispheres. Functional and
structural studies emphasized the central role of PC in a
wide spectrum of abilities and it participates to the “default
mode network” (DMN) a specific, anatomically defined brain
system preferentially active when individuals are not focused
on the external environment but participate in internal
modes of cognition [25].
PC is selectively connected with other parietal structures
(parietal caudal operculum and parietal lobules) for the
processing of visuospatial information [26–28] and to the
premotor cortex [29, 30], playing a central role in the visual
coordination of hand and reaching movements [31].
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Subcortical connections of PC are also relevant. They
seem to come from the BA 31 region, which is a cortical
transition zone from themedial parietal areas to the posterior
cingulate and presents an apparent shift in cytoarchitecture
from parietal isocortex to limbic cortex [32]. These projec-
tions reach several thalamic nuclei, the dorsolateral caudate
nucleus, the putamen, the zona incerta, and, mainly, the
brainstem structures such as the pretectal area, the superior
colliculus, and the nucleus reticularis tegmenti pontis [33].
This last pathway, which brings together fibers coming from
IPC, is functionally connected to the retinotectal visual
system (RTVS), an ancient and subconscious visual network
processing several visual parameters, as quality of oculo-
motor movements, contrast and colour discrimination, early
impaired in PD and strongly involved in themotor behaviour
[34].
The AG, particularly on the right side, is involved in
higher-order aspects of motor control: the awareness that an
intended action is consistent with movement consequences
and the awareness of the authorship of the action (called
“sense of agency”). Specifically, this region seems to process
discrepancies between intended action andmovement conse-
quences in such a way that these will be consciously detected
by the subject, ability that seems to be compromised in PD
patients [35].
The structures of the parietal cortex play a central role
in the networks which underlie both sustained attention on
current task goals and various forms of response to salient
stimuli in the environment to adapt to changing circum-
stances. In humans, the rostral part seems to be involved in
motor planning and action-related functions and it is a part
of the humanmirror neuron system [36–39].The right caudal
parietal cortex is involved in spatial and nonspatial attention
as well asmotor preparation [40, 41], while left caudal parietal
cortex is active during language-related tasks [42, 43]. This
hemispheric specialization could explain prevalent atrophy
observed in the right side because visuospatial functions,
unlike linguistic ones, are often impaired in early PD [44].
Therefore, GMatrophy of the parietal structures observed
in our early PD patients can be interpreted as the neu-
roanatomical correlate of visuospatial symptoms which we
know to start early and often during the premotor phase.
4.3. Midbrain. At follow-up, an additional region of
decreased grey volume was found in the midbrain. A similar
cluster could be detected at baseline at a less conservative
threshold. This cluster was located in the posterior region
of the midbrain corresponding to the MLR of cat [16]; in
humans it includes the pedunculopontine nucleus (PPN),
the cuneiform nucleus, the periaqueductal gray, and the
locus coeruleus [45, 46]. It receives inputs from basal ganglia,
limbic system and supplementary and premotor cortex and
it sends its main efferents to the basal ganglia, the brainstem,
and the spinal cord [47].
With respect to the cellular density twomain subdivisions
of the mammals PPN have been recognized: a pars compacta
of PPN (PPNc), constituted by cholinergic neurons; a pars
dissipata (PPNd), containing a large proportion of glutamin-
ergic neurons [48, 49].
Animal studies revealed a fundamental role of this struc-
ture in supraspinal locomotor circuit implicated in control of
posture and gait, in particular for the rhythm and fluidity of
step. In the decerebrate cat it has been shown [50] that 50Hz
stimulation of the MLR (corresponding to human PPNd)
increased muscle tone and induced alternating hind limb
stepping movements, enabling locomotor movements when
the treadmill started to move. In the same experiment stim-
ulation of PPN (corresponding to human PPNc) decreased
muscle tone.
Anatomical and neurophysiological human studies con-
firmed such roles of MLR/PPN, in particular in the modula-
tion of posture and gait initiation [47]. In a recent fMRI study
on healthy subjects [51], mental imagery of stance and loco-
motion induced activation of cortical and subcortical areas
including cerebellum, PPN, and cuneiform nucleus. This
cluster resembled the MLR observed in the cat and demon-
strated its similarity with the human locomotor network.
Hathout and Bhidayasiri [52] described three patients
with ischemic lesions in the posterior midbrain tegmentum,
corresponding to the cluster observed in our study. In
addition to ataxia and vertical gaze palsy, probably related
to the superior cerebellar pathways (CPS) and to third and
fourth nerve impairment, all patients presented a start of
hesitation and short and irregular steps without other motor
parkinsonian signs.
We know that some axial symptoms in advanced PD,
like a beginning hesitation, loss of steps rhythmicity, festi-
nation, and freezing, may be not dopa-responder and may
depend on the involvement of cholinergic mesencephalic
centers. In patients with progressive supranuclear palsy, PD,
and Parkinson-Dementia, neuropathologic studies showed
a strong loss of cholinergic neurons of PPN, correlating
with the severity of disease [47, 53, 54]. Based on these
observations some authors choose PPN as target of deep
brain stimulation (DBS) in PD improving gait and other
axial symptoms [55, 56]. Studying this model, Ballanger
and collaborators showed that unilateral PPN-DBS increased
rCBF in different subcortical area interconnected with PPN
especially in cerebellum, thalamus, and a brainstem region
corresponding to MLR [57].
In a recent VBM-fMRI study Snijders et al. [58] showed
the presence, in PD patients with freezing of gait compared
with nonfreezers, of an area of atrophy in a small posterior
area of themidbrain corresponding to theMLR.Moreover, in
the same patients, an fMRI study ofmotor imagery has shown
an area of functional activation in the MLR, probably due to
loss of balance between excitatory and inhibitory neurons in
attempting to support gait planning and execution [58].
Our study confirmed the presence of GM atrophy in
MLR. It is important to underline that, differently to Snijders
and collaborators, we observed these data also in mild/
moderate stage of PD, in which no patient had a clinically
relevant gait or postural disorder. These data suggest an early
impairment of MLR/PPN in PD and its specific role in the
pathogenesis of postural and gait disorders.
5. Conclusions
The classical theory of the PD evolution developed by
Braak did not receive convincing and univocal support by
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the neuroimaging techniques. A recent point of view [59]
opposes the fixed temporal ordering of the caudal-cephalic
propagation patterns of pathological lesions proposed by
Braak et al. This new theory confers a role to the “archaic
neural networks” consisting of parts of basal ganglia, mid-
brain, and parietal regions. An early frailty of this system
could produce disrupted automatic gait control, olfactory
and visual deficits, impaired emotional face recognition, and
REM sleep behavior disorder that are the premotor core of
PD. Our data, which show an early atrophy of putamen,
parietal cortex and MLR, structures large enough to detect
the atrophy, seem to support this hypothesis.
Although the small sample size prevents correcting the
results for multiple comparison, our study shows that struc-
tural MRI measurement methods could be used to identify
the presence of brain atrophy in specific regions known to be
associated with PD pathogenesis, also before the occurrence
of clinical symptoms. Furthermore this study has highlighted
a progression of atrophy correlated with clinical worsening
of patients. We hope that our results will shed light on the
neuropathological progression of the PD pathology.
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